Increased frequency of GM-CSF secreting PBMC in patients with active systemic lupus erythematosus can be reduced by immunoadsorption

Abstract

An objective was to determine the frequency of GM-CSF secreting peripheral blood mononuclear cells (PBMC) in patients with active systemic lupus erythematosus (SLE) and their relation to other cytokine secreting PBMC, activation markers on lymphocytes/monocytes, clinical manifestations and anti- dsDNA antibodies.A second objectivewas to further investigatethe influence of immunoadsorption(IA) therapy on these parameters.The number of GM-CSF, interleukin-1b (IL-1b), IL-6, interferon-g (INF-g) or tumour necrosis factor-a (TNF-a) secreting PBMC was assessed by ELISPOT assay in 10 patients with active SLE. Further, the expression of activation markers on lymphocytes and monocytes was determined by flow cytometry. Three courses of IA were performed in the patients. Seventeen healthy, age- and sex-matched volunteers served as controls. GM-CSF secreting PBMC were significantly increased whereas INF-g secreting cells were decreased in SLE patients. The expression of CD71 (transferrin receptor) on CD4 + T-cells and of the costimulatorymolecule CD86 on B-lymphocyteswas significantly increased in SLE patients. GM-CSF secreting PBMC and CD4 + /CD71 + T-cells correlated with anti-dsDNA antibody titres and decreased towards levels of controls during IA. Disease activity and anti-dsDNA autoantibody titres were significantly reduced after the treatment. Our results demonstrate significant alterations of cellular and humoral immunity in SLE patients. The impaired immunity can be modulated by IA. Thus IA may prove an immunomodulatory therapeutic option in addition to the mere depletion of anti-dsDNA autoantibodies.

Keywords

ELISPOT GM-CSF immunoadsorption systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

al-Janadi M , Raziuddin S. B cell hyperactivity is a function of T cell derived cytokines in systemic lupus erythematosus . J Rheumatol 1993; 20: 1885-1891 .

Hamilton JA. GM-CSF in inflammation and autoimmunity . Trends Immunol 2002; 23: 403-408 .

Ibelgaufts H. Granulocyte-macrophage colony-stimulating factor. In: Ibelgaufts H (ed) Dictionary of Cytokines. Wiley: Basel , 1994, 290-296.

Kruger M , Van Gool S , Peng XH , Coorevits L , Casteels-Van Daele M , Ceuppens JL. Production of granulocyte-macrophage colony-stimulating factor by T cells is regulated by B7 and IL-1 beta . Immunology 1996; 88: 49-54 .

Hamilton JA. Colony stimulating factors, cytokines and monocytemacrophages - some controversies . Immunol Today 1993; 14: 18-24 .

Campbell IK , Rich MJ , Bischof RJ , Dunn AR , Grail D , Hamilton JA. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice . J Immunol 1998; 161: 3639-3644 .

Braun N , Erley C , Klein R , Kotter I , Saal J , Risler T. Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus . Nephrol Dial Transplant 2000; 15: 1367-1372 .

Gaubitz M , Seidel M , Kummer S et al. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus . J Autoimmun 1998; 11: 495-501 .

Sun KH , Yu CL , Tang SJ , Sun GH. Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis . Immunology 2000; 99: 352-360 .

10.

Neng LK , Leung JC , Bik LK , Li PK , Lai CK. Anti-DNA autoantibodies stimulate the release of interleukin-1 and interleukin-6 from endothelial cells . J Pathol 1996; 178: 451-457 .

11.

Braun N , Risler T. Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease . Ther Apher 1999; 3: 240-245 .

12.

Willeke P , Schotte H , Erren M , et al. Concomitant reduction of disease activity and IL-10 secreting peripheral blood mononuclear cells during immunoadsorption in patients with active systemic lupus erythematosus . Cell Mol Biol 2002; 48: 323-329 .

13.

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271-1277 .

14.

Liang MH , Socher SA , Larson MG , Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus . Arthritis Rheum 1989; 32: 1107-1118 .

15.

Vaquerano JE , Peng M , Chang JW , Zhou YM , Leong SP. Digital quantification of the enzyme-linked immunospot (ELISPOT) . Biotechniques 1998; 25: 830-834 .

16.

Fiehn C , Wermann M , Pezzutto A , Hufner M , Heilig B. Plasma GM-CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy . Z Rheumatol 1992; 51: 121-126 .

17.

Starkebaum G. Chronic neutropenia associated with autoimmune disease . Semin Hematol 2002; 39: 121-127 .

18.

Liu MF , Li JS , Weng TH , Lei HY. Differential expression and modulation of costimulatory molecules CD80 and CD86 on monocytes from patients with systemic lupus erythematosus . Scand J Immunol 1999; 49: 82-87 .

19.

Sfikakis PP , Via CS. Expression of CD28, CTLA4, CD80, and CD86 molecules in patients with autoimmune rheumatic diseases: implications for immunotherapy . Clin Immunol Immunopathol 1997; 83: 195-198 .

20.

Shirakawa F , Yamashita U , Suzuki H. Decrease in HLA-DR-positive monocytes in patients with systemic lupus erythematosus (SLE) . J Immunol 1985; 134: 3560-3562 .

21.

Steinbach F , Henke F , Krause B , Thiele B , Burmester GR , Hiepe F. Monocytes from systemic lupus erythematous patients are severely altered in phenotype and lineage flexibility . Ann Rheum Dis 2000; 59: 283-288 .

22.

Döcke WD , Reinke P , Taffa G et al. An immune monitoring program for the management of immunosuppressive therapy in the early phase after transplantation . Transplantationsmedizin 1994; 6: 13-28 .

23.

Hagiwara E , Gourley MF , Lee S , Klinman DK. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: interferon-gamma-secreting cells in the peripheral blood . Arthritis Rheum 1996; 39: 379-385 .

24.

Kox WJ , Volk T , Kox SN , Volk HD. Immunomodulatory therapies in sepsis . Intens Care Med 2000; 26(Suppl): 124-128 .

25.

Llorente L , Zou W , Levy Y et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus . J Exp Med 1995; 181: 839-844 .

26.

Hayashi M , Dorf ME , Abromson-Leeman S. Granulocyte-macrophage colony stimulating factor inhibits class II major histocompatibility complex expression and antigen presentation by microglia . J Neuroimmunol 1993; 48: 23-32 .

27.

May WS Jr , Cuatrecasas P. Transferrin receptor: its biological significance . J Membr Biol 1985; 88: 205-215 .

28.

Rastellini C , Braun M , Li X et al. Prolongation of pancreatic islet graft survival by blocking transferrin receptor (CD71) . Transplant Proc 2001; 33: 518-519 .

29.

Vallin H , Perers A , Alm GV , Ronnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus . J Immunol 1999; 163: 6306-6313 .

30.

Portales-Perez D , Alarcon-Segovia D , Llorente L et al. Penetrating anti-DNA monoclonal antibodies induce activation of human peripheral blood mononuclear cells . J Autoimmun 1998; 11: 563-571 .